← All trials
NCT05443464
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 5, 2023
- Primary completion
- Jun 10, 2024
- Completion date
- Oct 14, 2024
- First posted
- Jul 5, 2022
- Last posted
- Dec 23, 2022
- Enrollment
- 0
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ossium Health, Inc.Lead sponsor
- Ossium Health, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.